Epidemiology of the diabetes-cardio-renal spectrum: cross-sectional report of 1.4 million adults | Cardiovascular Diabetology

  • Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, Regional, and National Diabetes Prevalence Estimates to 2021 and Projections to 2045. Diabetes Res Clin Pract. 2022;183: 109119.

    Google Scholar Article

  • GBD Collaboration Chronic Kidney Disease. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the 2017 Global Burden of Disease Study. Lancet. 2020;395(10225):709–33.

    Google Scholar Article

  • Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021. https://doi.org/10.1093/eurjpc/zwaa147.

    Article PubMed Google Scholar

  • Braunwald E. Diabetes, heart failure and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62(4):298–302.

    Google Scholar Article

  • Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic changes and therapeutic interventions: a review of the state of the art by the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243–54.

    Article CAS Google Scholar

  • Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and manifestation of chronic kidney disease and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22(9):1607–18.

    Article CAS Google Scholar

  • Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–39.

    Google Scholar Article

  • Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: an American Heart Association scientific statement. Circulation. 2019;139(16):e840–78.

    Google Scholar Article

  • Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes receiving thiazolidinediones: a meta-analysis of randomized controlled trials. Lancet. 2007;370(9593):1129–36.

    Article CAS Google Scholar

  • Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial. Lancet. 2019;393(10184):1937–47.

    Article CAS Google Scholar

  • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with type 2 diabetic nephropathy. N Engl J Med. 2001;345(12):851–60.

    Article CAS Google Scholar

  • IST. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.

    Google Scholar Article

  • Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid antagonism and diabetic kidney disease. Curr Diab Rep. 2019;19(1):4.

    Google Scholar Article

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article CAS Google Scholar

  • Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    Article CAS Google Scholar

  • McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

    Article CAS Google Scholar

  • Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

    Article CAS Google Scholar

  • Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

    Article CAS Google Scholar

  • Verma S, Juni P, Mazer CD. Pump, Tubes and Filter: Do SGLT2 Inhibitors Cover It All? Lancet. 2019;393(10166):3–5.

    Google Scholar Article

  • Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, et al. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021. https://doi.org/10.2337/dc21-0076.

    Article PubMed PubMed Central Google Scholar

  • Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2021. https://doi.org/10.1016/S2213-8587(21)00295-3.

    Article PubMed Google Scholar

  • Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, et al. DCRM Multispecialty Practice Recommendations for the treatment of diabetes, cardiorenal and metabolic diseases. J Diabetes Complicat. 2021;7: 108101.

    Google Scholar

  • Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large healthcare organization. Int J Cardiol. 2011;152(3):345–9.

    Google Scholar Article

  • Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2003;18(12):1143–6.

    Google Scholar Article

  • Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med. 2017;15(1):199.

    Google Scholar Article

  • Magliano DJ, Chen L, Islam RM, Carstensen B, Gregg EW, Pavkov ME, et al. Trends in the incidence of diagnosed diabetes: a multinational analysis of pooled data from 22 million diagnoses in high- and middle-income settings. Lancet Diabetes Endocrinol. 2021;9(4):203–11.

    Google Scholar Article

  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Google Scholar Article

  • Savarese G, Lund LH. Global public health burden of heart failure. Rev card failure. 2017;3(1):7–11.

    Google Scholar Article

  • Kornowski R, Orvin K. Current Status of Cardiovascular Medicine in Israel. Circulation. 2020;142(1):17–9.

    Google Scholar Article

  • Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Prevalence, incidence and mortality of heart failure in elderly people with diabetes. Diabetes Care. 2004;27(3):699–703.

    Google Scholar Article

  • Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and the Heart Failure Society of America. J card failure. 2019;25(8):584–619.

    Google Scholar Article

  • Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The new biology of diabetic kidney disease – mechanisms and therapeutic implications. Endoc Rev. 2020. https://doi.org/10.1210/endrev/bnz010.

    Article PubMed Google Scholar

  • Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care. 2017;40(11):1597–605.

    Google Scholar Article

  • Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis of DAPA-HF. Diabetes Care. 2021;44(2):586–94.

    Article CAS Google Scholar

  • Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, et al. Association between diabetes mellitus and post-discharge outcomes in hospitalized patients with heart failure: findings from the EVEREST study. Eur J Heart Fail. 2013;15(2):194–202.

    Article CAS Google Scholar

  • Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation. 2019;140(19):1569–77.

    Article CAS Google Scholar

  • Heerspink HJL, Kohan DE, Zeeuw D. New insights from SONAR indicate that the addition of sodium glucose cotransporter 2 inhibitors to an endothelin receptor antagonist attenuates fluid retention and enhances the reduction in albuminuria. Kidney Int. 2021;99(2):346–9.

    Article CAS Google Scholar

  • van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, et al. Effect of twice daily exenatide and dapagliflozin, alone and in combination, on markers of renal function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021;23(8):1851–1858.

  • Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36–45.

    Google Scholar Article

  • Epidemiology of the diabetes-cardio-renal spectrum: cross-sectional report of 1.4 million adults | Cardiovascular Diabetology

    Leave a Reply

    Your email address will not be published.

    Scroll to top